600196.SS Decision Brief — research Fosun Pharma before you trade it
The 600196.SS decision brief turns one ticker into a written research decision. This page shows the workflow and the current scanner snapshot for Fosun Pharma; the live scored brief runs inside Balance Labs.
Balance Labs is an AI stock research workspace: AI Stock Chat, a Berkshire-style fundamentals desk, Stock Screener timing signals across US / HK / China A-share / Korea / India, and Labs backtesting. Free plan includes Stock Chat and the Screener preview with 30 monthly AI credits.
Key facts — quick answer
- 600196.SS = Fosun Pharma, listed on the China A-share market (sector: Pharma).
- Scanner snapshot 2026-08-28: last price ¥22.84 · engine signal LONG · open uPnL -3.6%.
- The free 600196.SS decision brief workflow: business quality → valuation ceiling → thesis breaks → timing.
600196.SS snapshot
| Snapshot | 2026-08-28 · source: tencent |
|---|---|
| Market | 🇨🇳 China A-share (600196.SS) |
| Sector | Pharma |
| Last price | ¥22.84 |
| Engine signal | LONG · open uPnL -3.6% |
| Signal age | 38 bars · total return -1.8% |
Snapshot values are from the Balance Labs Stock Scanner (daily bars, multi-source public data) on 2026-08-28. They describe state, not a forecast.
How the 600196.SS analysis workflow works
- Business quality — Fosun Pharma is scored on the Berkshire-style fundamentals desk, not on opinion.
- Valuation ceiling — stress-test price assumptions with the free intrinsic value calculator.
- Thesis breaks — write the measurable failure conditions before buying.
- Timing — only after the first three pass, check the Screener signal above.
Method end-to-end: AI stock research workflow · worked examples: valuation ceiling and thesis breaks.
Run the live 600196.SS brief free
Open Stock Chat on 600196.SS — the workspace assembles fundamentals score, valuation math, thesis checklist, and Screener timing. Open the 600196.SS brief
Run it on live data — free
Stock Chat + Screener preview · 30 monthly AI credits. Real-time scanner across US, Hong Kong, China A-shares, Korea, and India.
FAQ
What is the 600196.SS decision brief?
The 600196.SS decision brief is the free Balance Labs research workflow applied to Fosun Pharma: business quality, a valuation ceiling, explicit thesis breaks, and Stock Screener timing. It is a research aid, not investment advice.
Is 600196.SS a good buy right now?
Balance Labs does not answer that with an opinion. The workflow scores the business, sets a valuation ceiling, and only then checks the current 600196.SS signal — snapshot 2026-08-28: LONG with open uPnL -3.6%. Run the live brief free inside Balance Labs for the current scored version.
How does the Fosun Pharma ADR/local shares analysis work for non-US investors?
Fosun Pharma trades on the China A-share market in ¥. The same four-part workflow applies; the Screener fetches daily bars through redundant public sources, so international tickers get the same treatment as US names.
What is the best pharmaceutical stock to buy right now?
That question sits inside the 600196.SS brief workflow: score quality, set the valuation ceiling, write the thesis breaks, then check the live Screener signal. The scored current version runs free inside Balance Labs.
Who owns Fosun Pharma?
The disciplined way to answer that is process, not opinion — Fosun Pharma gets scored on quality, priced against an earnings-power ceiling, and tracked for named thesis breaks before timing is even considered. Snapshot 2026-08-28 is shown above.
What is the most undervalued pharma stock?
Balance Labs treats that as a workflow question: open the free 600196.SS brief and the workspace assembles the fundamentals score, valuation math, and current LONG signal — so the answer comes from scored data, not a hot take.
Get more Balance Labs in your Google results
Add balancelabs.app as a Preferred Source on Google to see our research in Search and AI Overviews.
← All guides · Home · Data snapshot 2026-08-28 · Not investment advice.